Buscar en
Clínica e Investigación en Arteriosclerosis (English Edition)
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis (English Edition) Role of newer antidiabetic drugs on cardiovascular prevention and heart failure
Journal Information
Vol. 33. Issue 6.
Pages 314-322 (November - December 2021)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 33. Issue 6.
Pages 314-322 (November - December 2021)
Review article
Role of newer antidiabetic drugs on cardiovascular prevention and heart failure
Rol de nuevos fármacos antidiabéticos en prevención cardiovascular e insuficiencia cardiaca
Visits
...
Jesús Miguel Rojas-Velázqueza,b,
Corresponding author
jesusmrojas96@gmail.com

Corresponding author.
, Alejandro Giralt-Herreraa,b, Jessica Leiva-Enríqueza,c, Jennifer Leiva-Enríqueza,d
a Universidad de Ciencias Médicas de La Habana, Playa, La Habana, Cuba
b Instituto de Cardiología y Cirugía Cardiovascular, La Habana, Cuba
c Policlínico Universitario Rampa, La Habana, Cuba
d Policlínico Universitario Héroes del Moncada, La Habana, Cuba
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Clinical trials which assess the impact of SGLT2i in cardiovascular outcomes.
Table 2. Clinical trials which assessed the impact of GLP-1ª in cardiovascular outcomes.
Table 3. Clinical trials which assessed the impact of DPP-4i in cardiovascular outcomes.
Show moreShow less
Abstract

Beyond glucemic control there are other important goals when it comes to providing integral care to patients with Diabetes Mellitus. A bibliographic review was made in order to identify the role played by new antidiabetic drugs in cardiovascular prevention and heart failure. The use of SLGT2i and GLP1a leads to a significant decrease in cardiovascular events, with no difference between the two, except when it comes to hospitalizations for heart failure, where the superiority of the last ones (especially dapaglifozin and empaglifozin) is evident. The current evidence regarding the effect of dpp-4i is diverse, although an increased risk of hospitalizations for heart failure is observed with the use of some drugs of this class (saxagliptin).

Keywords:
Sodium-glucose co-transporter 2 inhibitor
Glucagon-like peptide-1 receptor agonists
Dipeptidylpeptidase-4 inhibitor
Heart failure
Myocardial ischemia
Type 2 diabetes mellitus
Resumen

Más allá del control de la glucemia existen otros objetivos importantes a la hora de brindar atención integral a pacientes con Diabetes Mellitus. Se realizó una revisión bibliográfica con el objetivo de identificar el papel que juegan los nuevos fármacos antidiabéticos en la prevención cardiovascular y la insuficiencia cardiaca. El uso de SGLT2i y GLP-1a acarrea una disminución significativa de eventos cardiovasculares, sin diferencias entre ambos, exceptuando las hospitalizaciones por insuficiencia cardiaca, en donde es evidente la superioridad de estos últimos (en especial dapaglifozina y empaglifozina). La evidencia actual respecto al efecto de los DPP-4i es diversa aunque se observa un aumento del riesgo de hospitalizaciones por insuficiencia cardiaca con el consumo de algunas drogas de esta clase (saxagliptina).

Palabras clave:
Inhibidores del cotransportador sodio/glucosa tipo 2
Agonistas del receptor del péptido similar al glucagón tipo 1
Inhibidores de la peptidil dipeptidasa 4
Insuficiencia cardiaca
Isquemia miocárdica
Diabetes mellitus tipo 2

Article

These are the options to access the full texts of the publication Clínica e Investigación en Arteriosclerosis (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Clínica e Investigación en Arteriosclerosis (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos